Last Updated | 31 March 2026

DAY101-001 (FIREFLY)

A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in paediatric Patients With BRAF-Altered, Recurrent or Progressive Low-Grade Glioma
External Registry
Site Status Queensland Children's Hospital Sydney Children's Hospital Perth Children's Hospital Children's Hospital at Westmead Royal Children's Hospital Women's and Children's Hospital
Queensland Children's Hospital (QLD)
John Hunter Children's Hospital (NSW)
Sydney Children's Hospital (NSW)
Monash Health Clayton (VIC)
Royal Children's Hospital (VIC)
Women's and Children's Hospital (SA)
Perth Children's Hospital (WA)
Royal Hobart Hospital (TAS)
Children's Hospital at Westmead (NSW)
Starship Children's Hospital (NZ)
Christchurch Hospital (NZ)
Preparing to Open
Open
Temporarily Closed
Closed
Complete
Adult Sites These sites are not monitored. Status may vary.
Diagnosis Stage Relapsed/Refractory
National Sponsor Day One Biopharmaceuticals, Inc.
Open Date 17/03/2021
Conditions Low-grade Glioma
Patient Range 6 months25 years
Disease Type Brain and Spinal (Central Nervous System) Tumours
Study Type Interventional
International Sponsor N/A

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

We are committed to creating a safe and welcoming environment that embraces all backgrounds, cultures, sexualities, genders and abilities.